San Diego Stock Exchange

SEARCH SAN DIEGO STOCKS:

Symbol

ACADIA PHARMACEUTICALS INC

Symbol	Name	Close	Change		Volume	Dayhigh	Daylow
ACAD	Acadia Pharma	1.01	-0.02	- 1.94%	173510.00	1.04	1.01

Exchange	Earningspershare	52-Week High	52-Week Low
NASDAQ N-Mkt	-1.20	2.08	0.99

SourceBook Information

Acadia Pharmaceuticals Inc. is listed in:

• Biomed & Biotech Firms -
• Biomed & Biotech Firms - Publicly Traded -
• Local Publicly Traded Companies -

Contact Information

Company Name

Acadia Pharmaceuticals Inc.

Executives

Leslie L. Iversen, Chairman

Uli Hacksell, CEO

Mark Brann, President/CSO

Address

3911 Sorrento Valley Blvd.

San Diego, CA 92121

Phone

(858) 558-2871

Fax

(858) 558-2872

E-mail

info@acadia-pharm.com

Web Page

www.acadia-pharm.com

Business Information

Parent Company

n/a

Business Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company has four drug programs in clinical development and in preclinical and discovery stages.

SIC Code

n/a

Headquarters

San Diego, CA

Local Mailing Address

3911 Sorrento Valley Blvd., San Diego, CA 92121

Year Established

1993

Year Established in San Diego

1993

Publicly Traded?

Yes

Ticker Symbol

ACAD

Market Capitalization

$54,437,650

Total Number of Employees

101

Number of Local Employees

101

Number of Offices Local

101

Gross Revenue 2000

n/a

Gross Revenue 2000 Year End

n/a

Gross Revenue 2001

n/a

Gross Revenue 2001 Year End

n/a

Gross Revenue 2002

n/a

Gross Revenue 2002 Year End

n/a

Gross Revenue 2003

$7,000,000

Gross Revenue 2003 Year End

$5,000,000

Gross Revenue 2004

$5,000,000

Gross Revenue 2005 YTD, Local

n/a

Gross Revenue 2007

n/a

Gross Revenue 2009

n/a

Gross Revenue 2010

n/a

Manufacturer

n/a

Mission Statement

n/a

Fields of Research

Central nervous system disorders

Major Products

Pimavanservin, ACP-104, drug discovery and development

Major Investors

n/a

Number of Products Approved For Sale

n/a

Patents

n/a

Number of Products In Development

n/a

Strategic Alliances

n/a

Services Offered

n/a

Chief Executive Officer

Uli Hacksell

Date CEO Began

2000

Total Annual CEO Compensation (salary & bonuses)

$436,000 (FY 2004)

CEO Salary

$317,000 (FY 2004)

CEO Bonuses

$119,000 (FY 2004)

Gross Revenue 2006

n/a

Sales for 2006

n/a

Gross Revenue 2008

n/a